Aequus Pharmaceuticals Inc. (AQS.V)
| Previous Close | 0.0350 |
| Open | 0.0400 |
| Bid | 0.0350 x 0 |
| Ask | 0.0500 x 0 |
| Day's Range | 0.0400 - 0.0500 |
| 52 Week Range | 0.0200 - 0.1100 |
| Volume | |
| Avg. Volume | 200,182 |
| Market Cap | 6.632M |
| Beta (5Y Monthly) | 0.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0110 |
| Earnings Date | Nov 01, 2022 - Nov 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.52 |
- GlobeNewswire
Aequus Announces Health Canada Notice of Compliance (NOC) for Zimed® Preservative Free (Bimatoprost 0.03%)
VANCOUVER, British Columbia, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), is pleased to announce that Health Canada has approved Zimed® PF (Bimatoprost 0.03%) for the reduction of elevated intraocular pressure (IOP) in patients with open-angled glaucoma or ocular hypertension. Affecting more than 700,000 people in Canada, glaucoma is one of the leading causes of blindness in North America. Zimed® PF is the first prostagland
- Simply Wall St.
Aequus Pharmaceuticals Third Quarter 2022 Earnings: CA$0.004 loss per share (vs CA$0.003 loss in 3Q 2021)
Aequus Pharmaceuticals ( CVE:AQS ) Third Quarter 2022 Results Key Financial Results Revenue: CA$347.9k (down 51% from...
- GlobeNewswire
Aequus Reports Third Quarter 2022 Financial Highlights
VANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, today reported financial results for the quarter ended September 30, 2022 (“Third Quarter 2022”) and associated Company developments. Unless otherwise noted, all figures are in Canadian currency. Financial Report Highlights Aequus reported
